Financials

  • Market Capitalization 401.54 M
  • Employee 45
  • Founded 2019
  • CEO N/A
  • Website www.x4pharma.com
  • Headquarter Delaware, United States
  • FIGI BBG001J1CYH8
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-2.14
Relación precio/flujo de caja
26.03

Related tickers

#NombrePrecio24h %7d %1M %1A %CapitalizaciónÚltimos 7 días
3051
LRMR
Larimar Therapeutics, Inc. - Common Stock
4.00 USD-1.23%-4.31%+4.99%+2.04%415.53 M USD
3061
GALT
Galectin Therapeutics Inc. - Common Stock
4.03 USD-2.66%+9.51%+17.49%-4.05%406.42 M USD
3076
CTNM
Contineum Therapeutics, Inc. - Common stock
17.00 USD-1.45%-1.11%+19.97%+11.33%392.69 M USD
3088
ENTA
Enanta Pharmaceuticals, Inc. - Common Stock
13.65 USD-1.09%+1.34%+8.68%+57.08%397.56 M USD

Noticias